skip to main content
Accomplished

Accomplishments are evidenced by approved products and an advancing pipeline. Seven marketed and partnered products validate our technology and development approach.

History

A Leader in Inhaled Pharmaceuticals

Collaborative

Our collaborative approach to drug development is seen both internally and in successful partnerships. Partners include Novartis, Sandoz, Baxter and GSK.

Partnering

A Leader in Inhaled Pharmaceuticals

Enabling

Our formulation technologies and proprietary devices enable delivery directly to the lungs and underpin the company’s development pipeline.

Formulation

A Leader in Inhaled Pharmaceuticals

Innovative

Know-how and experience fuels innovation. Our experienced teams of scientists focus on developing innovative solutions in all areas of drug development.

Devices

A Leader in Inhaled Pharmaceuticals

Focused

Our drug development efforts are focused on bronchopulmonary disease - a high unmet need and growing multi billion market.

Investors

A Leader in Inhaled Pharmaceuticals

Vectura is a respiratory product development Company. Enabled by our high-quality proprietary technologies, our experienced employees work hard to ensure we continue to be one of the leading names within our sector.

Our products

Our innovative and broad clinical pipeline combines mid- and late-stage programmes with earlier-stage opportunities addressing large and fast-growing market sectors

View our product pipeline

In focus

Vectura establishes strategic partnership (Kinnovata) for new respiratory business in China.

Chippenham, UK – 13 May 2013:Vectura Group plc (LSE: VEC) ("Vectura"), announces that it has established Tianjin Kinnovata Pharmaceutical Company Limited ("Kinnovata") in China with two partners; Tianjin KingYork Group Company Limited ("KingYork"), a leading Chinese pharmaceutical company and specialist manufacturer of corticosteroid based products, and Zendex Bio Strategy Inc ("Zendex"), a private equity investor based in Hong Kong.

Read more